Today we celebrate #WorldHealthDay. OLON contributes to fight against global pandemics. We play a key role for the access to therapies, providing active principles that treat major global diseases such as tuberculosis, sickle cell disease, leprosy. This is key for global issues and it is a focus for OLON. Our mission is to challenge and innovate the way to deliver science, to improve the health of all human beings. For #WorldHealthDay we remind how relevant it is to believe in science as a solution to promote health and to improve the quality of #life. We are committed, as key player of the pharmaceutical supply chain, to be innovative every day, #researching and #developing.
OLON has been awarded by the Prize Industria Felix 2021 to be one the best companies for its international vocation, performance of management and financial reliability.
IndustriaFelix is one of the most influencing events about economy and finance among Italian press. The Prize is a full recognition creativity, fervour and determination to those who demonstrate the capacity to build an enterprise producing significative results in terms of social wealth and economic progress.
The companies have been selected by a skilled Scientific Committee, after a journalist survey that analysed 142 thousand financial reports. Among these, the Commission has awarded the 43 most competitive corporations, based in Lombardia, considering management performance, financial reliability, sustainability. These corporations, including Olon, have received The Financial Management Honour of the Prize Industria Felix.
The mission of Industria Felix is promoting a network between valuable companies to promote the image of Italian competitiveness.
“We are proud to be awarded by this prestigious Prize that proves our key role, not only in the chemistry industry but also in the social and economic fabric of Lombardia Region” has commented Drssa Roberta Pizzocaro, President of Olon “Olon contributes to the competitiveness of Lombardia Region considering that our performance let us double our size over the last few years”.
Government is already working to accelerate inclusion of the medicine and associated laboratory testing in the National Health Insurance Scheme
Novartis has already delivered more than 20 000 treatments1 and is committed to implementing two clinical trials with novel biologic treatment for sickle cell disease
Partnership includes establishing national treatment guidelines, newborn screening, and centers of excellence for treatment of sickle cell disease; making accessible treatment options available in line with the global standards of care; and using digital technologies to monitor and evaluate patient registration, report real-time data, and help ensure safe large scale roll-out of medicine
15 000 babies are born with sickle cell disease every year in Ghana2
Accra, Ghana, November 6, 2019 – Today, the Government of Ghana announced the availability of hydroxyurea for the treatment of people with sickle cell disease (SCD), marking the official launch of a first of its kind public-private partnership to improve the diagnosis and accelerate treatment for people with SCD.
The launch follows the signature of a Memorandum of Understanding in January among the Ministry of Health of Ghana, Ghana Health Service, the Sickle Cell Foundation of Ghana and global medicines company Novartis to create a holistic approach to help manage the disease. Ghana is the first African country to commit to offering the global standard of care for their people with SCD. “I am proud of this bold partnership, and it is my hope that, through this collaboration, we will help ease the pain and improve the lives of people living with sickle cell disease in our country. We are committed to put SCD among the priorities on our national health agenda and to take the necessary steps to make treatment broadly available through our National Health Insurance Scheme, bringing much-needed relief to families struggling to cover the cost of care for their loved ones,” said H.E. Alhaji Dr. Mahamudu Bawumia, Vice President of the Republic of Ghana. “Our collective goal is to reimagine what the future could look like for people with sickle cell disease: where children do not need to miss out on school or be singled out; where young adults can have equal opportunity for employment; and where families can flourish and continue to be the bedrock of our civil society—in a nutshell, we will make every effort to ‘normalize’ sickle cell disease within the Ghanaian society.”
To date, Novartis has delivered more than 20 000 treatments of hydroxyurea. Initially, the therapy will be made available through 11 trained treatment centers, as well as through private distribution channels, and is expected to cover the needs of patients for up to 12 months. The partners aim to open more treatment centers by the end of the year, and Novartis is committed to delivering a total of 60 000 treatments. Discussions are aleady underway for inclusion of the medicine and associated laboratory testing in the National Health Insurance Scheme, as well as prioritizing SCD as a national program.
Hydroxyurea is a commonly used medicine for patients with SCD in developed countries, and is approved for use in both adults and children. In October 2018, the Ghana FDA granted marketing authorization to Novartis hydroxyurea, making it the first time that hydroxyurea will be available for this indication in Ghana. A recent study, published in the New England Journal of Medicine3 indicates that hydroxyurea treatment is effective and safe in children with SCD in sub-Saharan Africa and reduces the incidence of pain events (vaso-occlusive crises), malaria, blood transfusions, and death.
“All the traditional names by which SCD is known allude to the episodes of severe pain experienced by people with the disease,” said Prof. Kwaku Ohene-Frempong, MD, President of the Sickle Cell Foundation of Ghana and Program Coordinator for the National Newborn Screening Program for Sickle Cell Disease. “Hydroxyurea is a drug with proven efficacy in reducing pain episodes and other complications of the disease. Currently, the highest standard of care for people with SCD starts with early diagnosis through newborn screening followed by penicillin prophylaxis to prevent early death from infection, and hydroxyurea therapy to ease the pain, prevent other complications and improve quality of life.”
At the same time, Novartis has committed to develop a child-friendly formulation of hydroxyurea and has announced plans to conduct two clinical trials in Ghana and Kenya for its next-generation treatment for SCD, crizanlizumab. Crizanlizumab is a novel targeted biologic therapy that is expected to help reduce pain crises in people with SCD. The trials are expected to start in 2020; this will be the first time that a biologic therapy, which is not a vaccine, enters multicenter clinical trials in sub-Saharan Africa (excluding South Africa)4.
“Novartis is deeply committed to reimagining medicine for patients in Ghana and across Africa,” said Vas Narasimhan, MD, CEO of Novartis. “Building on our long heritage of addressing malaria and leprosy in Africa, we’re excited to help improve the diagnosis and treatment of people with sickle cell disease here in Ghana. Novartis is proud to join this pioneering partnership, which could accelerate efforts to forge a healthier future for children across the continent.”
Sickle cell disease is recognized by the World Health Organization as a public health priority and a neglected health problem in sub-Saharan Africa. Approximately 80% of individuals with
SCD globally are born in sub-Saharan Africa, and there is evidence to suggest that more than half of affected individuals may die before the age of five due to preventable complications. In Ghana, it is estimated that 15 000 babies are born with sickle cell disease every year2.
The five-year partnership aims to improve and extend the lives of people with SCD through a comprehensive approach to screening and diagnosis; treatment and disease management; training and education; and elevating basic and clinical research capabilities. Specifically, the partners aim to collaborate on field testing and implementation of SCD treatment guidelines, the establishment of centers of excellence across regions and the implementation of newborn screening at these centers. In addition, partners plan to employ digital technologies to monitor and evaluate patient registration, report real-time data and help ensure safe large scale roll-out of medicine.
In parallel, Novartis is working with Zipline, a California-based automated logistics company, to make sickle cell treatments widely available, especially in rural areas. Zipline is already operating two distribution centers in Ghana, in Omenako and Asante Mampong, with plans to open two more in the near future.
In addition, in order to help further ensure a sustainable supply of high quality hydroxyurea, Novartis has entered a strategic collaboration with Olon, a manufacturer based in Italy that supplies the active ingredient for the drug. “We are proud to collaborate with Novartis and its partners to help make hydroxyurea more broadly available and in a sustainable way,” said Paolo Tubertini, CEO of Olon. “As a demonstration of our commitment to patients with sickle cell disease and this program, we will also contribute, without cost, the active ingredient to cover approximately 12 000 thousand treatments. Our hope is to continue to meet the needs and challenges of those living with sickle cell disease and their families to improve access to quality health care.”
About Sickle Cell Disease Sickle cell disease is a deblitating, inherited blood disorder. It causes affected red blood cells to become sickle-shaped, stiff and fragile – easily breaking apart. Blood vessels and blood cells become sticky due to damage caused by sickle cells and ongoing chronic inflammation5,6. That leads to blood cells sticking to each other and to the blood vessels and causing blockages – called vaso-occlusion – which can lead to the acute episodes of pain (known as sickle cell pain crises or vaso-occlusive crises), stroke and other life-threatening complications5,7. It is a lifelong illness that can put an emotional, physical, and financial burden on patients and their families8,9.
SCD is a global health problem, with the highest burden of disease concentrated in sub-Saharan Africa. In countries in West, Central and East Africa, the prevalence of the sickle cell gene is between 10 to 30 percent, while in some areas it is as high as 45%10. It is estimated that approximately 1 000 children in Africa are born with SCD every day and more than half die before they reach five years of age11. This is due primarily to lack of early diagnosis through newborn screening, penicillin prophylaxis, parental education, and comprehensive care. In resource-poor countries, more than 90 percent of children with SCD do not survive to adulthood12. Despite the adoption by the WHO of an SCD strategy for Africa in 2010, the disease is largely absent from the global or national health agenda.
One treatment equals one month’s supply for an adult patient above 33kg of weight
Odame I. Perspective: We need a global solution. Nature. 2014 Nov;515(7526):S10
Scott D. Grosse, Isaac Odame, Hani K. Atrash, et al. Sickle Cell Disease in Africa: A Neglected Cause of Early Childhood Mortality. American Journal of Preventive Medicine 41, no. S4 (December 2011): S398-405.
Bernadette Modell and Matthew Darlison. Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization 86, no. 6 (June 2008): 480-487.
Corporate QualityControl, R&D, Regulatory Affairs and M&S, OLON has developed a comprehensive Corporate Quality Policy to support at the best our Customers’ related needs in the changing regulatory scenario that involves the current Nitrosamine situation.OLON already started the confirmatory tests execution in line with the Agencies expectation thanks to the analytical Know-How gained, new OrbitrapSpectrometer and fluent support from certificated partners labs.
Olon, one of That’s Nice’s Road to 2021 sponsors, discusses how the company is innovating to face the challenges of the COVID-19 pandemic and beyond to face the future of healthcare.
Innovation is a key focus for Olon and is reflected in both the mission and vision: Olon aims to create new ideas and devise pathways to deliver prompt and sustainable solutions for the life science industry and innovate new ways to improve the health of all human beings. The development of innovative and original technology platforms is one of our main drivers as a CDMO supplying APIs to pharmaceutical companies worldwide.
Olon values people, expertise, and dedication, and constantly invests in new and different technologies, as well as its existing resources. To remain innovative, Olon executes training and improvement programs in R&D and other important technical areas.
Innovation — in terms of optimization and improvement of processes — is key to the services that Olon always provides to its customers. Olon continues to invest in its capabilities for chemical synthesis, fermentation, and biologics. One innovation that is particularly crucial to Olon going forward is the adoption of continuous rather than batch processing for API manufacturing. This transition will have a significant impact on how the company does business, from R&D to quality, regulatory, and manufacturing. Olon has been asked to make substantial contributions toward the global health efforts to contain Covid-19.
Olon is also closely eyeing innovations in genomic mapping that can result in increasing the selectivity of high-potency drugs. Such results can impact both formulation and production, leading to more tailored, personalized drugs for smaller patient groups. This transition to personalized medicine will mean an increase in the development and manufacture of smaller-volume drugs, which will, in turn, influence the size of the reactors that are required. Smaller-volume manufacturing will have an impact on pricing, as development costs will increase as they are divided among fewer, more select patients. Olon is looking to increase its high-containment capabilities with the goal of taking on a greater number of highly potent API (HPAPI) projects. Owing to the considerable potential of these products, Olon is carefully weighing short- and longterm impacts on the development process to find ways to contain potential cost increases resulting from investments in new capabilities. Innovating During the COVID-19 Pandemic In the context of the COVID-19 pandemic, the lockdown of some supplier countries has underscored the criticality of a robust supply chain. Olon is working to minimize the impact on disruptions from low-cost countries, with the goal of maintaining sufficient diversification of supply to avoid production interruptions, a goal that existed prior to the current crisis.
Olon has been asked to make substantial contributions toward the global health efforts to contain COVID-19. Olon was selected by three innovator companies to produce new experimental antiviral drugs, and all three are currently in advanced clinical trials phases. The company is excited about the opportunity to contribute in such a meaningful way during this challenging period.
We are pleased to communicate that an area of OLON F1 production plant, at Rodano site, has received the SMEPAC certification.
The plant includes lines 3 and 4 for the production of High Potent Active Ingredients (HAPI) with high containment, recognized OEB4 and OEB5, thanks to the use of specific technologies such as filter driers, isolators for powder loading and unloading (gloveboxes) and high-tech confined areas.
The plant allows to handle substances in isolation according to a scale that varies from OEB1 to OEB5, where OEB5 represents the maximum containment value and that is why, the high performance attributed to our plant, is for us a big potential for the production lines.
The emphasis that this type of plant has received in the last few years is mainly due to the desire to minimize the impact of the manipulation and synthesis of chemicals on the external environment.
For this reason, the production and handling processes of the High Potent Active Ingredients must be carried out safely in equipment that keeps all the material being processed inside it, creating a protective barrier between the operator/external environment and inside the equipment.
Even our new containment pilot plant at Segrate has received the #SMEPAC certification.Congratulations for this new success!!
OLON con l’ONU per una nuova sostenibilità 17 gli Obiettivi per lo Sviluppo Sostenibile che l’ONU ha proposto con un piano al 2030 e al quale OLON, grazie alle sue 11 sedi nel mondo, sente di poter dare un contributo.
I 193 Paesi Membri dell’ONU hanno identificato alcuni dei temi più caldi sui quali costruire un piano di sviluppo Sostenibile per garantire un programma per le persone, il pianeta e la prosperità, i 17 obiettivi sono declinati in un grande programma d’azione per un totale di 169 obiettivi o traguardi, per citare alcuni:
lotta alla povertà;
lotta al cambiamento climatico;
riduzione delle disuguaglianze;
promozione della salute e del benessere;
Azioni che il Gruppo OLON ha da subito voluto integrare nel proprio piano di sviluppo e di crescita.
L’impegno è partito con l’integrazione di quote rosa, che in OLON già rappresentano una forte risorsa, soprattutto nelle cariche più alte e supporto ai Comuni ospitanti che, oltre ad appoggiare i nostri siti, rappresentano una delle fonti principali delle nostre forze lavoro.
Consapevole delle differenze culturali e delle sfide associate all’interpretazione e applicazione di questi principi legati all’etica, al lavoro, alla salute e alla sicurezza, per promuovere la sostenibilità ambientale a livello globale, OLON ha deciso di prefissarsi autonomamente i seguenti obiettivi 2025:
Riduzione del consumo di energia per ridurre le emissioni di CO2 e di gas serra (-50% di emissioni di CO2 specifiche, per tonnellata di prodotti nel periodo 2015-2025);
Riduzione del consumo di acqua specifico per promuovere un uso equo e sostenibile (-50% nel periodo 2015-2025);
Riduzione dei rifiuti specifici generati, aumentandone il recupero (-40% periodo 2015-2025)
Aumento della formazione su sicurezza, salute e ambiente del personale (nel 2025 almeno 8 ore a persona);
Progetto “zero infortuni” con target a 0.
E siamo solo al 2025…ora del 2030 riusciremo a fare ancora meglio
Tante le attività iniziate e in crescita, che in pochi mesi hanno portato a creare una nuova sezione dedicata allo scopo, presente anche nel sito web consultabile al link: http://olonspa.com/sustainability/
OLON crede fermamente che le persone, la salute, la sicurezza e la protezione dell’ambiente siano gli elementi più importanti per il raggiungimento dei propri obiettivi. Per questo motivo, rappresentano allo stesso tempo valori per l’azienda e impegno nello sviluppo del proprio business.
Seguendo questi principi, OLON promuove, assicura, valuta, sviluppa, seleziona le migliori pratiche e mantiene costante attenzione all’ambiente, alle relazioni, all’aspetto umano, al codice etico e ai bisogni locali. Quest’ idea si basa sulla convinzione che un’azienda debba operare nel pieno rispetto di tutte le leggi, norme e regolamenti applicabili per il proprio settore
OLON is a privileged company that, like others, has the benefit and the commitment of continuing industrial activities to produce medicines.
This makes us think about our role: we represent a value for the community and not only for ourselves.Aware of this, we opened a specific aid program towards all Italian municipalities in which we operate as they are the first structures facing the difficulties of citizens and will proceed on this way.Some examples of the initiatives we support are: the distribution of masks to citizens in the Municipality of Casaletto Lodigiano; the activation of the psychological listening service in the Municipality of Dorno; the purchase of material for the Red Cross of the Municipality of Capua; free meals for people in difficulty in the Municipality of Mulazzano … and many others.If we can contribute to our communities it is also thanks to the dedication and resilience that all our employees are showing; for this, we wish to extend the thanks received from the Mayors to all of them.
Olon has been interviewed by Pharma’s Almanac about future investments target.
Olon, one of our Road To CPhI Milano sponsors discuss how they are preparing to face the future of healthcare. The Mission of the Company After a string of recent acquisitions, Olon has updated the company mission and vision to reflect goals for 2020 and beyond. This mission now reads to “Challenge and innovate the way we deliver science to improve the health of all human beings.” This means that Olon is committed to stepping back to analyze every decision objectively. They will also implement “creative ideas, creating a pathway for prompt and sustainable solutions in the life science industry.” This gives Olon the flexibility and opportunity needed to step outside the box, finding new and sustainable solutions to their clients’ complex problems.
The importance of Olon’s work cannot be overestimated, as their efforts bring positive changes to the lives of millions of human beings across the globe. They drive timelines for bringing new medication to patients, delivering quality and affordable treatments. In just two years, Olon has doubled in size. In 2017, the company acquired three plants from Infa group — two plants are located in Italy (Segrate and Casaletto) and one is in Spain (Derivados Quimicos, in Murcia). In 2019, Olon acquired Capua Bioservices, with a facility in Italy and a former Novartis site in Mahad, India. With a total network of 11 manufacturing plants, Olon is a production leader for APIs.
The company has also recently invested in new technologies aiming to increase production capabilities. These investments include a fluorination plant, where synthesis can take place using hydrofluoric acid and its derivatives, and in flow chemistry. The company is committed to positively transitioning from a classic batch system to continuous manufacturing, saving on cost and decreasing environmental impact. They have heavily invested in expanding their capacity using high-containment technology (reaction/isolation/drying/micronization). They are also introducing spray drying and wet milling, which are the new frontiers of the drying and granulation processes, and lead to higher production performances. In November 2019, Olon announced a collaboration with Novartis to ensure the sustainable supply of high-quality hydroxyurea in Ghana and other African countries. Hydroxyurea is commonly used to treat both adults and children with sickle cell disease. In October 2018, Ghana’s FDA granted marketing authorization to hydroxyurea, making it the first time that the drug was available for this indication in Ghana. Olon is proud to collaborate with Novartis and its partners to help make hydroxyurea more broadly available in a sustainable way. As a demonstration of their commitment to patients with sickle cell disease, and this program, Olon has sponsored approximately 12,000 treatments of hydroxyurea. Following the updated mission and vision based on creativity, sustainability, and the improvement for all human beings’ lives, Olon is focused on developing innovative products in cooperation with customers and on an exclusive basis, as they continue to be a reliable partner for pharma companies. The company has plans for future growth and is evaluating new M&A opportunities.
Capua BioServices Spa (OLON Biotech), parte del gruppo OLON SpA, grazie al supporto derivante dal programma di finanziamento europeo Horizon 2020 – PON 2014/2020, sta conducendo con successo il progetto di ricerca industriale e sviluppo sperimentale dal titolo: “Studio e progettazione di un sistema innovato Multipurpose di R&D per enzimi a scopo terapeutico, con focus particolare su enzimi destinati alla cura di malattie rare e intermedi di base sviluppati mediante processi biotecnologici”Capua BioServices (OLON Biotech) vuole inserirsi, attraverso questo progetto innovativo, come partner in grado di offrire innovazioni tecnologiche ed intellettuali, che permettono di accelerare i tempi, di ridurre sensibilmente i costi legati alla realizzazione di impianti necessari a rendere disponibile un prodotto biotech sul mercato.